| Health / Medical Topics |
HLA-A*2402-Restricted URLC10 Peptides Vaccine
A cancer vaccine containing HLA-A*2402-restricted epitope peptides URLC10 (up-regulated lung cancer 10) with potential immunostimulatory and antineoplastic activities. Upon administration, HLA-A*2402-restricted URLC10 peptides vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells. URLC10, a tumor associated antigen, is often overexpressed in lung, esophageal and gastric cancers. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. (NCI Thesaurus)
YOU MAY ALSO LIKE
A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted…
A cancer vaccine containing five HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from…
A cancer vaccine containing five HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from…
A cancer vaccine containing two HLA-A*2402-restricted peptide epitopes derived from cancer-testis antigens with potential immunostimulatory and antitumor activities. The peptide epitopes are…
A cancer vaccine containing the HLA-A*2402-restricted peptide epitope derived from cell division associated gene 1 (CDCA1), with potential immunostimulatory and antitumor…
A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from:…
